Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/prokidney-corp">ProKidney </a>is a late-stage biotechnology company developing a potentially disruptive, first-in-class autologous cell therapy, rilparencel (REACT), aimed at restoring kidney function in patients with advanced chronic kidney disease (CKD).</li>
  <li>The primary value inflection point is the anticipated release of pivotal topline data from the Phase 3 PROACT 1 study in the second quarter of 2027, which will assess the surrogate endpoint of eGFR slope for potential accelerated FDA approval.</li>
  <li>The company is pre-revenue and operates with a significant net loss, funded by its cash reserves of $224.9 million as of Q1 2026, which are projected to support operations into mid-2027. Future capital raises are highly probable to fund ongoing trials and potential commercialization.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
ProKidney is a late-stage biotechnology company developing a potentially disruptive, first-in-class autologous cell therapy, rilparencel (REACT), aimed at restoring kidney function in patients with advanced chronic kidney disease (CKD).
  The primary value inflection point is the anticipated release of pivotal topline data from the Phase 3 PROACT 1 study in the second quarter of 2027, which will assess the surrogate endpoint of eGFR slope for potential accelerated FDA approval.
  The company is pre-revenue and operates with a significant net loss, funded by its cash reserves of $224.9 million as of Q1 2026, which are projected to support operations into mid-2027. Future capital raises are highly probable to fund ongoing trials and potential commercialization.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

ProKidney Corp operates as a biotech company. The Company develops therapies that repairs and restores diseased kidneys using a patient's own cells and may prevent or delay dialysis or transplant. ProKidney serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ProKidney (PROK US)

Primer: ProKidney (PROK US) - Aug 2026

ProKidney is a late-stage biotechnology company developing a potentially disruptive, first-in-class autologous cell therapy, rilparencel...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)